非霍奇金淋巴瘤合并乙型肝炎病毒感染的研究进展
|
摘要
<正>非霍奇金淋巴瘤(non Hodgkin′s lymphoma,NHL)是以淋巴结肿大为首要表现,伴有全身症状,多见淋巴结外受累和远处扩散的一类发病机制尚不完全清楚的恶性肿瘤,是造血系统常见肿瘤之一,其发病及死亡率已占恶性肿瘤的前10位[1]。乙型肝炎病毒(HBV)感染是全球性问题,以地区性而言,据相关资料[2]显示我国人口HBV的感染率在8%~20%。而NHL合并HBV感染在临
Hepatitis B virus(HBV)infection was commonly found among non-Hodgkin′s lymphoma(NHL)patients.With the increasing awareness of the disease,more and more research about the pathogenesis and treatment have been conducted to study non-Hodgkin′s lymphoma with hepatitis B virus infections.In this review,we summarize the relationship between HBV infection and non-Hodgkin′s lymphoma and its treatment.
Hepatitis B virus(HBV)infection was commonly found among non-Hodgkin′s lymphoma(NHL)patients.With the increasing awareness of the disease,more and more research about the pathogenesis and treatment have been conducted to study non-Hodgkin′s lymphoma with hepatitis B virus infections.In this review,we summarize the relationship between HBV infection and non-Hodgkin′s lymphoma and its treatment.
引文
[1]Takamatsu Y,Suzumiya J,Utsunomiya A,et al.THPCOP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemid/lymphoma:a multicenter phaseⅡstudy[J].Eur J Haematol,2010,84(5):391-397.
[2]Luo GL,Zhao XH.Non Hodgkin′s lymphoma with viral hepatitis of Bclinical analysis[J].Zhongguo Shiyong Yiyao,2011,6(13):108-110.(in Chinese)罗广立,赵晓红.非霍奇金淋巴瘤并病毒性乙型肝炎临床分析[J].中国实用医药,2011,6(13):108-110.
[3]Marcucci F,Mele A,Spada E,et al.High prevalence of hepatitis B virus infection in B-cell non-Hodgkin′s lymphoma[J].Haematologica,2006,91(4):554-557.
[4]Park SC,Jeong SH,Kim J,et al.High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin′s lymphoma in Korea[J].J Med Virol,2008,80(6):960-966.
[5]Luo LH,Fan Y,Huang ZY,et al.Correlation of hepatitis B virus infection and non Hodgkin′s lymphoma[J].Zhonghua Zhongliu Fangzhi Zazhi,2010,17(18):1413-1417.(in Chinese)罗吕宏,范云,黄志熠,等.乙型肝炎病毒感染与非霍奇金淋巴瘤相关性的研究[J].中华肿瘤防治杂志,2010,17(18):1413-1417.
[6]Chen MH,Hsiao LT,Chiou TJ,et al.High prevalence of occult hepatitis B virus infection in patients with B cell nonHodgkin′s lymphoma[J].Ann Hematol,2008,87(6):475-480.
[7]Wang F,Xu RH,Han B,et al.High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers[J].Cancer,2007,109(7):1360-1364.
[8]Wang L,Xie XH,Chen YJ,et al.Analysis of the incidence of malignant lymphoma in China risk factor Meta[J].Shiyong Zhongliu Zazhi,2010,25(4):477-479.(in Chinese)王琳,谢贤和,陈岩菊,等.中国人群恶性淋巴瘤发病危险因素的Meta分析[J].实用肿瘤杂志,2010,25(4):477-479.
[9]Zheng D,Wang SY,Wang W,et al.257cases of non Hodgkin′s lymphoma in patients with hepatitis B virus infection analysis[J].Yixue Zongshu,2012,18(13):2119.(in Chinese)郑丹,王树叶,王巍,等.257例非霍奇金淋巴瘤患者乙型肝炎病毒感染分析[J].医学综述,2012,18(13):2119.
[10]Lu YT,Huang HH.Non Hodgkin′s lymphoma with hepatitis B virus infection after chemotherapy,hepatitis virus reactivation research progress[J].Zhongliu,2009,29(2):191-193.(in Chinese)陆莹婷,黄洪晖.非霍奇金淋巴瘤合并乙型肝炎病毒感染经化疗后肝炎病毒再激活研究进展[J].肿瘤,2009,29(2):191-193.
[11]Guo JR.Clinical analysis of lymphoma chemotherapy induced by reactivation of hepatitis B virus adefovir dipivoxil in prevention of hepatitis B with non after Hodgkin[J].Yixue Zongshu,2010,16(23):3665-3666.(in Chinese)郭江睿.阿德福韦酯预防乙型肝炎携带的非霍奇金淋巴瘤化疗后致乙肝病毒再激活的临床分析[J].医学综述,2010,16(23):3665-3666.
[12]Zeng AP,Yu QT,Zhou SZ,et al.To observe the curative effect of rituximab combined with CHOP regimen in the treatment of diffuse large B cell lymphoma[J].Zhongguo Aizheng Fangzhi Zazhi,2013,5(2):153.(in Chinese)曾爱屏,于起涛,周韶璋,等.美罗华联合CHOP方案治疗弥漫性大B细胞淋巴瘤的疗效观察[J].中国癌症防治杂志,2013,5(2):153.
[13]Rossi D,Rasi S,Franceschetti S,et al.Analysis of the host phamacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphomatreated with RCHOP21[J].Leukemia,2009,23(6):1118-1126.
[14]Wang JY.Medicine[M].Beijing:People′s Medicine Publishing House,2011:822.(in Chinese)王吉耀.内科学[M].北京:人民卫生出版社,2011:822.
[15]Ye X,Li HC,Zhang XL,et al.The MINE scheme to save the treatment of 36cases of non Hodgkin′s lymphoma[J].Shiyong Zhongliu Zazhi,2007,22(2):130-131.(in Chinese)叶娴,李汉冲,张晓黎,等.MINE方案挽救治疗36例非霍奇金淋巴瘤[J].实用肿瘤杂志,2007,22(2):130-131.
[16]Oyan B,Koc Y,Ozdemir E,et al.Ifosfamide,idarubicin,and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma:a salvage regimen with high response rates before autolog ousstem cell transplantation[J].Biol Blood Marrow Transplant,2005,11(9):688-697.
[17]Biagi JJ,Herbert KE,Smith C,et al.A phaseⅡstudy of dexamethasone,ifosfamide,cisplat in and etoposide(DICE)as salvage chemotherapy for patients with relapsed and refractory lymphoma[J].Leuk Lymphoma,2005,46(2):197-206.
[18]Olivieri A,Brunori M,Capelli D,et al.Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantion in 79lymphoma patients:an intention to mobilize and transplant analysis[J].Eur J Haematol,2004,72(1):10-17.
[19]Liang M,Shang Y,Gong QY.Effect of ProMACE-CytaBOM regime in the treatment of non Hodgkin′s lymphoma[J].Zhongguo Yishi Zazhi,2006,8(1):136.(in Chinese)梁敏,尚勇,龚启英.ProMACE-CytaBOM方案治疗非霍奇金淋巴瘤的近期疗效观察[J].中国医师杂志,2006,8(1):136.
[20]Zhu ZM,Zhou JF,Yuan XL.IVAG regimen in the treatment of refractory and relapsedcurative effect observation of27cases of non Hodgkin′s lymphoma[J].Zhonghua Shiyong Zhenduan Yu Zhiliao Zazhi,2013,27(1):98.(in Chinese)朱尊民,周剑锋,袁晓莉.IVAG方案治疗难治性复发性非霍奇金淋巴瘤27例近期疗效观察[J].中华实用诊断与治疗杂志,2013,27(1):98.
[21]Zhao L.Combination therapy for relapsed,refractory non Hodgkin′s lymphoma:analysis of 27cases[J].Zhongguo Wuzhenxue Zazhi,2006,12(6):2369.(in Chinese)赵璐.联合治疗复发、难治性非霍奇金淋巴瘤27例分析[J].中国误诊学杂志,2006,12(6):2369.
[22]Du XH,Pei RZ,Ma JX,et al.High dose methotrexate combined with chemotherapy in the treatment of refractory or relapsed non Hodgkin′s lymphoma[J].Xiandai Shiyong Yixue,2006,18(3):167.(in Chinese)杜小红,裴仁治,马俊霞,等.大剂量甲氨蝶呤联合化疗治疗难治或复发非霍奇金淋巴瘤[J].现代实用医学,2006,18(3):167.
[23]Zhang LS,Chen DB,Wang BQ,et al.State analysis of lymphoma with hepatitis B virus infection in non Hodgkin[J].Xiandai Zhongliu Yixue,2010,18(5):1005-1006.(in Chinese)张兰胜,陈冬波,王保庆,等.非霍奇金淋巴瘤患者乙型肝炎病毒感染状态分析[J].现代肿瘤医学,2010,18(5):1005-1006.
[24]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chineses Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010version)[J].Zhongguo Bingdubing Zazhi,2011,1(1):9-19.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中国病毒病杂志,2011,1(1):9-19.
[25]Ziakas PD,Karsaliakos P,Mylonakis E,et al.Effect of prophylactic lamivudine for chem otherapy-associated hepatitis B reactivation in lymphoma:a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance[J].Haematologica,2009,94(7):998-1005.
[26]Experts Attending the Discussion on Hepatitis B Virus Drug Resistant.Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management[J].Zhongguo Bingdubing Zazhi,2013,3(1):1-8.(in Chinese)参加乙型肝炎病毒耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].中国病毒病杂志,2013,3(1):1-8.
[27]Zelenetz AD,Wierda WG,Abramson JS,et al.Non-Hodgkin′s lymphoma,version 1.2013[J].J Natl Compr Canc Netw,2013,11(3):257-272,quiz 273.
[28]EASL.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
[29]Li WL,Ma XY,Wu L,et al.Randomized controlled trial of telbivudine and lamivudine in the treatment of chronic long-term efficacy and safety in patients with hepatitis B[J].Yaowu Buliangfanying Zazhi,2010,12(2):77-82.(in Chinese)李蔚莉,马秀云,吴璐,等.替比夫定与拉米夫定长期治疗慢性乙型肝炎患者疗效与安全性的随机对照研究[J].药物不良反应杂志,2010,12(2):77-82.
[30]Zhan M,Wu FB,Wu B,et al.System evaluation of telbivudine in the treatment of chronic hepatitis B[J].Zhongguo Xunzheng Yixue Zazhi,2011,11(1):101-105.(in Chinese)占美,吴逢波,吴斌,等.替比夫定与拉米夫定比较治疗慢性乙肝疗效的系统评价[J].中国循证医学杂志,2011,11(1):101-105.
[31]Zhang JC,Nie QH.The treatment of chronic hepatitis B drug tenofovir ester[J].Shijie Huaren Xiaohua Zazhi,2008,16(24):2679-2688.(in Chinese)张久聪,聂青和.治疗慢性乙型肝炎新药——替诺福韦酯[J].世界华人消化杂志,2008,16(24):2679-2688.
[32]Luo DX,Huang MJ,Zhang XX,et al.Salvage treatment with erlotinib after gefitinib failure in advanced non-smallcell lung cancer patients with poor performance status:a matched-pair case-control study[J].Thoracic Cancer,2011,3(1):27-33.
[33]Costa DB,Nguyen KS,Cho BC,et al.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib[J].Clin Cancer Res,2008,14(21):7060-7067.
[34]Zheng W,Liu WP,Wang GQ,et al.Attention should be paid to the prevention and treatment of hepatitis B virusattack in the treatment of malignant lymphoma[J].Zhongguo Zhongliu Linchuang Yu Kangfu,2009,16(5):464-465.(in Chinese)郑文,刘卫平,王贵强,等.恶性淋巴瘤治疗中应重视乙型肝炎发作的预防和治疗[J].中国肿瘤临床与康复,2009,16(5):464-465.
[35]Tonziello G,Pisaturo M,Sica A,et al.Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma[J].Infection,2013,41(1):225-229.
[36]Fan Y,Luo C,Luo LH,et al.Retrospective analysis of hepatitis B virus reactivation after rituximab combination chemotherapy in patients with B-cell lymphoma[J].Chinese-German J Clin Oncol,2011,10(12):721-725.
[37]Ma YF.Relationship between non Hodgkin lymphoma patientscondition and prognosis of hepatitis B virus infection[J].Linchuang Yiyao Shijian,2011,20(3):173-175.(in Chinese)马爻芳.非霍奇金淋巴瘤患者乙型肝炎病毒感染状况与预后的关系[J].临床医药实践,2011,20(3):173-175.
[38]Huang LH,Yao YP.Antiviral therapy of HBV infection during chemotherapy[J].Shijie Huaren Xiaohua Zazhi,2011,19(15):1604-1608.(in Chinese)黄利华,姚悦萍.HBV感染者化疗时的抗病毒治疗[J].世界华人消化杂志,2011,19(15):1604-1608.
[2]Luo GL,Zhao XH.Non Hodgkin′s lymphoma with viral hepatitis of Bclinical analysis[J].Zhongguo Shiyong Yiyao,2011,6(13):108-110.(in Chinese)罗广立,赵晓红.非霍奇金淋巴瘤并病毒性乙型肝炎临床分析[J].中国实用医药,2011,6(13):108-110.
[3]Marcucci F,Mele A,Spada E,et al.High prevalence of hepatitis B virus infection in B-cell non-Hodgkin′s lymphoma[J].Haematologica,2006,91(4):554-557.
[4]Park SC,Jeong SH,Kim J,et al.High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin′s lymphoma in Korea[J].J Med Virol,2008,80(6):960-966.
[5]Luo LH,Fan Y,Huang ZY,et al.Correlation of hepatitis B virus infection and non Hodgkin′s lymphoma[J].Zhonghua Zhongliu Fangzhi Zazhi,2010,17(18):1413-1417.(in Chinese)罗吕宏,范云,黄志熠,等.乙型肝炎病毒感染与非霍奇金淋巴瘤相关性的研究[J].中华肿瘤防治杂志,2010,17(18):1413-1417.
[6]Chen MH,Hsiao LT,Chiou TJ,et al.High prevalence of occult hepatitis B virus infection in patients with B cell nonHodgkin′s lymphoma[J].Ann Hematol,2008,87(6):475-480.
[7]Wang F,Xu RH,Han B,et al.High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers[J].Cancer,2007,109(7):1360-1364.
[8]Wang L,Xie XH,Chen YJ,et al.Analysis of the incidence of malignant lymphoma in China risk factor Meta[J].Shiyong Zhongliu Zazhi,2010,25(4):477-479.(in Chinese)王琳,谢贤和,陈岩菊,等.中国人群恶性淋巴瘤发病危险因素的Meta分析[J].实用肿瘤杂志,2010,25(4):477-479.
[9]Zheng D,Wang SY,Wang W,et al.257cases of non Hodgkin′s lymphoma in patients with hepatitis B virus infection analysis[J].Yixue Zongshu,2012,18(13):2119.(in Chinese)郑丹,王树叶,王巍,等.257例非霍奇金淋巴瘤患者乙型肝炎病毒感染分析[J].医学综述,2012,18(13):2119.
[10]Lu YT,Huang HH.Non Hodgkin′s lymphoma with hepatitis B virus infection after chemotherapy,hepatitis virus reactivation research progress[J].Zhongliu,2009,29(2):191-193.(in Chinese)陆莹婷,黄洪晖.非霍奇金淋巴瘤合并乙型肝炎病毒感染经化疗后肝炎病毒再激活研究进展[J].肿瘤,2009,29(2):191-193.
[11]Guo JR.Clinical analysis of lymphoma chemotherapy induced by reactivation of hepatitis B virus adefovir dipivoxil in prevention of hepatitis B with non after Hodgkin[J].Yixue Zongshu,2010,16(23):3665-3666.(in Chinese)郭江睿.阿德福韦酯预防乙型肝炎携带的非霍奇金淋巴瘤化疗后致乙肝病毒再激活的临床分析[J].医学综述,2010,16(23):3665-3666.
[12]Zeng AP,Yu QT,Zhou SZ,et al.To observe the curative effect of rituximab combined with CHOP regimen in the treatment of diffuse large B cell lymphoma[J].Zhongguo Aizheng Fangzhi Zazhi,2013,5(2):153.(in Chinese)曾爱屏,于起涛,周韶璋,等.美罗华联合CHOP方案治疗弥漫性大B细胞淋巴瘤的疗效观察[J].中国癌症防治杂志,2013,5(2):153.
[13]Rossi D,Rasi S,Franceschetti S,et al.Analysis of the host phamacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphomatreated with RCHOP21[J].Leukemia,2009,23(6):1118-1126.
[14]Wang JY.Medicine[M].Beijing:People′s Medicine Publishing House,2011:822.(in Chinese)王吉耀.内科学[M].北京:人民卫生出版社,2011:822.
[15]Ye X,Li HC,Zhang XL,et al.The MINE scheme to save the treatment of 36cases of non Hodgkin′s lymphoma[J].Shiyong Zhongliu Zazhi,2007,22(2):130-131.(in Chinese)叶娴,李汉冲,张晓黎,等.MINE方案挽救治疗36例非霍奇金淋巴瘤[J].实用肿瘤杂志,2007,22(2):130-131.
[16]Oyan B,Koc Y,Ozdemir E,et al.Ifosfamide,idarubicin,and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma:a salvage regimen with high response rates before autolog ousstem cell transplantation[J].Biol Blood Marrow Transplant,2005,11(9):688-697.
[17]Biagi JJ,Herbert KE,Smith C,et al.A phaseⅡstudy of dexamethasone,ifosfamide,cisplat in and etoposide(DICE)as salvage chemotherapy for patients with relapsed and refractory lymphoma[J].Leuk Lymphoma,2005,46(2):197-206.
[18]Olivieri A,Brunori M,Capelli D,et al.Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantion in 79lymphoma patients:an intention to mobilize and transplant analysis[J].Eur J Haematol,2004,72(1):10-17.
[19]Liang M,Shang Y,Gong QY.Effect of ProMACE-CytaBOM regime in the treatment of non Hodgkin′s lymphoma[J].Zhongguo Yishi Zazhi,2006,8(1):136.(in Chinese)梁敏,尚勇,龚启英.ProMACE-CytaBOM方案治疗非霍奇金淋巴瘤的近期疗效观察[J].中国医师杂志,2006,8(1):136.
[20]Zhu ZM,Zhou JF,Yuan XL.IVAG regimen in the treatment of refractory and relapsedcurative effect observation of27cases of non Hodgkin′s lymphoma[J].Zhonghua Shiyong Zhenduan Yu Zhiliao Zazhi,2013,27(1):98.(in Chinese)朱尊民,周剑锋,袁晓莉.IVAG方案治疗难治性复发性非霍奇金淋巴瘤27例近期疗效观察[J].中华实用诊断与治疗杂志,2013,27(1):98.
[21]Zhao L.Combination therapy for relapsed,refractory non Hodgkin′s lymphoma:analysis of 27cases[J].Zhongguo Wuzhenxue Zazhi,2006,12(6):2369.(in Chinese)赵璐.联合治疗复发、难治性非霍奇金淋巴瘤27例分析[J].中国误诊学杂志,2006,12(6):2369.
[22]Du XH,Pei RZ,Ma JX,et al.High dose methotrexate combined with chemotherapy in the treatment of refractory or relapsed non Hodgkin′s lymphoma[J].Xiandai Shiyong Yixue,2006,18(3):167.(in Chinese)杜小红,裴仁治,马俊霞,等.大剂量甲氨蝶呤联合化疗治疗难治或复发非霍奇金淋巴瘤[J].现代实用医学,2006,18(3):167.
[23]Zhang LS,Chen DB,Wang BQ,et al.State analysis of lymphoma with hepatitis B virus infection in non Hodgkin[J].Xiandai Zhongliu Yixue,2010,18(5):1005-1006.(in Chinese)张兰胜,陈冬波,王保庆,等.非霍奇金淋巴瘤患者乙型肝炎病毒感染状态分析[J].现代肿瘤医学,2010,18(5):1005-1006.
[24]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chineses Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010version)[J].Zhongguo Bingdubing Zazhi,2011,1(1):9-19.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中国病毒病杂志,2011,1(1):9-19.
[25]Ziakas PD,Karsaliakos P,Mylonakis E,et al.Effect of prophylactic lamivudine for chem otherapy-associated hepatitis B reactivation in lymphoma:a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance[J].Haematologica,2009,94(7):998-1005.
[26]Experts Attending the Discussion on Hepatitis B Virus Drug Resistant.Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management[J].Zhongguo Bingdubing Zazhi,2013,3(1):1-8.(in Chinese)参加乙型肝炎病毒耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].中国病毒病杂志,2013,3(1):1-8.
[27]Zelenetz AD,Wierda WG,Abramson JS,et al.Non-Hodgkin′s lymphoma,version 1.2013[J].J Natl Compr Canc Netw,2013,11(3):257-272,quiz 273.
[28]EASL.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
[29]Li WL,Ma XY,Wu L,et al.Randomized controlled trial of telbivudine and lamivudine in the treatment of chronic long-term efficacy and safety in patients with hepatitis B[J].Yaowu Buliangfanying Zazhi,2010,12(2):77-82.(in Chinese)李蔚莉,马秀云,吴璐,等.替比夫定与拉米夫定长期治疗慢性乙型肝炎患者疗效与安全性的随机对照研究[J].药物不良反应杂志,2010,12(2):77-82.
[30]Zhan M,Wu FB,Wu B,et al.System evaluation of telbivudine in the treatment of chronic hepatitis B[J].Zhongguo Xunzheng Yixue Zazhi,2011,11(1):101-105.(in Chinese)占美,吴逢波,吴斌,等.替比夫定与拉米夫定比较治疗慢性乙肝疗效的系统评价[J].中国循证医学杂志,2011,11(1):101-105.
[31]Zhang JC,Nie QH.The treatment of chronic hepatitis B drug tenofovir ester[J].Shijie Huaren Xiaohua Zazhi,2008,16(24):2679-2688.(in Chinese)张久聪,聂青和.治疗慢性乙型肝炎新药——替诺福韦酯[J].世界华人消化杂志,2008,16(24):2679-2688.
[32]Luo DX,Huang MJ,Zhang XX,et al.Salvage treatment with erlotinib after gefitinib failure in advanced non-smallcell lung cancer patients with poor performance status:a matched-pair case-control study[J].Thoracic Cancer,2011,3(1):27-33.
[33]Costa DB,Nguyen KS,Cho BC,et al.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib[J].Clin Cancer Res,2008,14(21):7060-7067.
[34]Zheng W,Liu WP,Wang GQ,et al.Attention should be paid to the prevention and treatment of hepatitis B virusattack in the treatment of malignant lymphoma[J].Zhongguo Zhongliu Linchuang Yu Kangfu,2009,16(5):464-465.(in Chinese)郑文,刘卫平,王贵强,等.恶性淋巴瘤治疗中应重视乙型肝炎发作的预防和治疗[J].中国肿瘤临床与康复,2009,16(5):464-465.
[35]Tonziello G,Pisaturo M,Sica A,et al.Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma[J].Infection,2013,41(1):225-229.
[36]Fan Y,Luo C,Luo LH,et al.Retrospective analysis of hepatitis B virus reactivation after rituximab combination chemotherapy in patients with B-cell lymphoma[J].Chinese-German J Clin Oncol,2011,10(12):721-725.
[37]Ma YF.Relationship between non Hodgkin lymphoma patientscondition and prognosis of hepatitis B virus infection[J].Linchuang Yiyao Shijian,2011,20(3):173-175.(in Chinese)马爻芳.非霍奇金淋巴瘤患者乙型肝炎病毒感染状况与预后的关系[J].临床医药实践,2011,20(3):173-175.
[38]Huang LH,Yao YP.Antiviral therapy of HBV infection during chemotherapy[J].Shijie Huaren Xiaohua Zazhi,2011,19(15):1604-1608.(in Chinese)黄利华,姚悦萍.HBV感染者化疗时的抗病毒治疗[J].世界华人消化杂志,2011,19(15):1604-1608.